

Corporate Office :
406, Silver Oaks Comm. Complex,
Opp. Arun Society, Paldi,
Ahmedabad-380 007. Gujarat, India.
Phone : 079-26584655
Fax : 079-26588054
CIN No. : L24231GJ2004PLC043861
E-mail : info@sakarhealthcare.com
Web : www.sakarhealthcare.com

Date: 7th February 2026

To
The Manager
Listing Compliance Department
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051, India

Symbol: SAKAR

Sub: Press Release - Consolidated and Standalone Unaudited Financial Results for the quarter and nine months ended December 31, 2025.

In continuation of outcome of Board meeting held on February 05, 2026 on the Consolidated and Standalone Unaudited Financial Results for the quarter and nine months ended December 31, 2025 we attach a copy of Press Release being issued by the Company.

This is for information and records.

Thanking You,

Yours faithfully,
FOR, SAKAR HEALTHCARE LIMITED

BHARAT SONI
COMPANY SECRETARY AND
COMPLIANCE OFFICER

Q3FY26 – Sakar Healthcare Records 62% YoY Revenue Growth EBITDA Rises 58%

Ahmedabad, 05th February 2026 : Sakar Healthcare Ltd [NSE: SAKAR, with a research-driven API-integrated EU GMP approved oncology orals and injection manufacturing unit, has announced its un-audited financial results for the quarter and nine months ended 31st December 2025.

Q3 & 9M FY26 Consolidated Financial Performance

Particulars (INR Lakhs)	Q3FY26	Q3FY25	Y-o-Y	9MFY26	9MFY25	Y-o-Y
Revenue from Operations	7,034.2	4,341.7	62%	18,063.9	12,734.3	42%
Gross Profit	3,480.5	2,078.5	67%	8,574.3	5,975.1	43%
<i>Gross Profit Margin (%)</i>	<i>49%</i>	<i>48%</i>		<i>47%</i>	<i>47%</i>	
EBITDA	1,859.3	1,175.8	58%	4,265.3	3,395.9	26%
<i>EBITDA Margin (%)</i>	<i>26%</i>	<i>27%</i>		<i>24%</i>	<i>27%</i>	
Profit After Tax	1,024.9	453.3	126%	1,946.0	1,174.1	66%
<i>PAT Margin</i>	<i>15%</i>	<i>10%</i>		<i>11%</i>	<i>9%</i>	

Business Highlights for Q3 & 9M FY26

- Completed over 50 Business Contracts with oncology products & over 40 discussions are ongoing
- Of 211 dossiers shared globally, 102 have been submitted and 11 have received Marketing Authorizations from Regulatory Authorities
- 21 of 32 developed oncology products dossiers shared; of which 11 dossiers have received approval (Abiraterone-1, Imatinib-1, Tamoxifen-1, Capecitabine-1, Gemcitabine-2, Carboplatin-2, Irinotecan-1, Docetaxel-2)
- Technology Transfer projects with oncology products are ongoing for Accord-Intas, Torrent-UK & Germany, Emcure, Glenmark, Zydus



Financial Highlights for Q3 & 9M FY26

- Revenue for Q3FY26 stood at ₹7,034 lakhs, reflecting 62% YoY growth. Performance was supported by new market authorizations with oncology products and strong demand across EU countries, alongside continued execution across key initiatives
- EBITDA increased to ₹1,859 lakhs, up 58% YoY; EBITDA margins stood at 26%
- Company delivered a strong improvement in profitability, with PAT margin at 15% expanding sharply YoY, reflecting operating leverage, improved efficiencies, and disciplined cost management.

Commenting on the Results, Mr. Sanjay Shah, Managing Director said,


Q3 has been a defining quarter for Sakar Healthcare, delivering strong growth across all key performance metrics. Our operational discipline and focused execution are now translating into scale, profitability and deeper global integration.

The quarter also strengthened our strategic position: our oncology facility has been approved as a manufacturing source for Accord Healthcare UK's Imatinib supplies to the EU, which is one of many more such oncology products to follow. Our portfolio has expanded to eleven marketing authorisations across Europe and emerging markets—significantly enhancing our export pipeline.



With additional dossiers under review, rising capacity utilisation and increasing visibility from global partners, we are well-positioned to end FY26 on a high note. FY27 will be a year of acceleration as new approvals ramp up and EU-linked supplies gain momentum. We remain committed to building Sakar into a globally trusted oncology partner.

About Sakar HealthCare Limited:

Established in 2004 and headquartered in Ahmedabad, Gujarat, Sakar Healthcare Limited is a publicly listed pharmaceutical manufacturer and exporter specializing in oncology, antibiotics, and general formulations. The company operates world-class, EU-GMP and WHO-GMP certified facilities equipped to manufacture oral solids, injectables, oral liquids, and high-potent oncology products. Sakar's oncology division at Bavla represents a research-driven, API-integrated facility focused on developing and commercializing complex cytotoxic formulations and APIs, underscoring its commitment to innovation and quality. With an extensive global footprint across more than 60 countries, Sakar serves as a trusted partner to multinational pharmaceutical companies through CDMO, CRAMS, and technology transfer collaborations. Driven by its vision to deliver world-class healthcare solutions that make lives healthier and more meaningful, Sakar continues to expand its presence across regulated markets through strong R&D capabilities, regulatory excellence, and sustainable manufacturing practices rooted in green chemistry principles.



Contact Details

Sakar HealthCare Limited	Investor Relations: MUFG Intime India Private Limited
	
CIN - L24231GJ2004PLC043861	Mr. Nikunj Seth Ms. Sejal Bhattar +91 9773397958 +91 7666736666 nikunj.seth@in.mpms.mufg.com sejal.bhattar@in.mpms.mufg.com
Mr. Dharmesh Thaker CFO info@sakarhealthcare.com	

Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company’s operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.